Based on the key indicators related to Vanda Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Vanda Pharmaceuticals is performing exceptionally good at this time. It has a great odds to report excellent financial results in December. At present, Vanda Pharmaceuticals' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 82.1 M, whereas Short and Long Term Debt Total is forecasted to decline to about 9 M. Key indicators impacting Vanda Pharmaceuticals' financial strength include:
The essential information of the day-to-day investment outlook for Vanda Pharmaceuticals includes many different criteria found on its balance sheet. An individual investor should monitor Vanda Pharmaceuticals' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Vanda Pharmaceuticals.
Net Income
2.63 Million
Vanda
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Average Inventory
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Revenue Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Liabilities
Stock Based Compensation
Total Cashflows From Investing Activities
Change To Inventory
Change To Netincome
Sale Purchase Of Stock
Investments
Change Receivables
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Other Cashflows From Investing Activities
Change To Operating Activities
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Short Term Debt
Common Stock
Property Plant Equipment
Short Term Investments
Net Receivables
Inventory
Intangible Assets
Net Tangible Assets
Retained Earnings Total Equity
Capital Surpluse
Deferred Long Term Liab
Non Current Liabilities Other
Net Invested Capital
Net Working Capital
Capital Stock
Capital Lease Obligations
Depreciation And Amortization
Interest Expense
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Selling General Administrative
Net Income Applicable To Common Shares
Net Income From Continuing Ops
Tax Provision
Reconciled Depreciation
Selling And Marketing Expenses
Probability Of Bankruptcy
Understanding current and past Vanda Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Vanda Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Vanda Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the presentation of Vanda Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Vanda Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Vanda Pharmaceuticals' management manipulating its earnings.
Vanda Pharmaceuticals Stock Summary
Vanda Pharmaceuticals competes with Ikena Oncology, Eliem Therapeutics, HCW Biologics, RenovoRx, and Tempest Therapeutics. Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia. Vanda Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 278 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Vanda Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Vanda Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Vanda Pharmaceuticals competition to find correlations between indicators driving Vanda Pharmaceuticals's intrinsic value. More Info.
Vanda Pharmaceuticals is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers . At present, Vanda Pharmaceuticals' Return On Equity is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Vanda Pharmaceuticals' earnings, one of the primary drivers of an investment's value.
Vanda Pharmaceuticals Systematic Risk
Vanda Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Vanda Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Vanda Pharmaceuticals correlated with the market. If Beta is less than 0 Vanda Pharmaceuticals generally moves in the opposite direction as compared to the market. If Vanda Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Vanda Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Vanda Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Vanda Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Vanda Pharmaceuticals Thematic Clasifications
Vanda Pharmaceuticals is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Vanda Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Vanda Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Vanda Pharmaceuticals growth as a starting point in their analysis.
Price Earnings To Growth Ratio
(1.52)
At present, Vanda Pharmaceuticals' Price Earnings To Growth Ratio is projected to slightly decrease based on the last few years of reporting.
Vanda Pharmaceuticals November 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Vanda Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Vanda Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Vanda Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Vanda Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Vanda Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Vanda Pharmaceuticals' price analysis, check to measure Vanda Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vanda Pharmaceuticals is operating at the current time. Most of Vanda Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vanda Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vanda Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vanda Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.